{"filing":{"accession_number":"0001193125-26-270358","cik":"0001652130","ticker":"NTLA","company_name":"Intellia Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"ntla-20260613.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-20260613.htm"},"events":[{"id":10945,"run_id":9595,"accession_number":"0001193125-26-270358","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Intellia Therapeutics announced positive Phase 3 clinical trial results for lonvo-z (NTLA-2002) in hereditary angioedema, demonstrating achievement of primary and key secondary endpoints with 87% reduction in attacks (p\u003c0.0001) and favorable safety data, supporting advancement toward anticipated 2027 U.S. launch and BLA submission.","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7398,"accession_number":"0001193125-26-270358","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure reports \"Additional Positive Phase 3 Results\" for lonvo-z in hereditary angioedema patients. This is a clinical trial milestone announcement rather than an earnings release (which reports financial results) or a traditional earnings release format. Positive Phase 3 data is material to a biotech investor's assessment of pipeline value and regulatory approval prospects, but does not fit neatly into the earnings_release category, which typically refers to quarterly/annual financial results. This clinical milestone is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:53:30.744586+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7399,"accession_number":"0001193125-26-270358","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports positive Phase 3 clinical trial results for lonvo-z (NTLA-2002) in hereditary angioedema, including achievement of primary and key secondary endpoints with statistically significant efficacy (87% reduction in attacks, p\u003c0.0001) and favorable safety data. While this is a material clinical development that would affect investor assessment of the company's pipeline and regulatory prospects, it does not fit neatly into the earnings_release category (no financial results) or any other specific event type. The results support advancement toward the anticipated 2027 U.S. launch and BLA submission, making this a significant clinical milestone warranting disclosure under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:53:30.744586+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7398,"accession_number":"0001193125-26-270358","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure reports \"Additional Positive Phase 3 Results\" for lonvo-z in hereditary angioedema patients. This is a clinical trial milestone announcement rather than an earnings release (which reports financial results) or a traditional earnings release format. Positive Phase 3 data is material to a biotech investor's assessment of pipeline value and regulatory approval prospects, but does not fit neatly into the earnings_release category, which typically refers to quarterly/annual financial results. This clinical milestone is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:53:30.744586+00:00","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-06-15"},{"id":7399,"accession_number":"0001193125-26-270358","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports positive Phase 3 clinical trial results for lonvo-z (NTLA-2002) in hereditary angioedema, including achievement of primary and key secondary endpoints with statistically significant efficacy (87% reduction in attacks, p\u003c0.0001) and favorable safety data. While this is a material clinical development that would affect investor assessment of the company's pipeline and regulatory prospects, it does not fit neatly into the earnings_release category (no financial results) or any other specific event type. The results support advancement toward the anticipated 2027 U.S. launch and BLA submission, making this a significant clinical milestone warranting disclosure under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:53:30.744586+00:00","company_name":"Intellia Therapeutics, Inc.","ticker":"NTLA","filing_date":"2026-06-15"}]}